Progression-Free Survival at Any Site

PFS at any site was the primary endpoint of the SIRFLOX study. The results did not show a statistically significant improvement of PFS at any site. SIR-Spheres® Y-90 resin microspheres are a liver-directed therapy and do not have an effect on metastases outside the liver.1

Progression-Free Survival in the Liver

The SIRFLOX study indicates that SIR-Spheres Y-90 resin microspheres in combination with first line chemotherapy, versus chemotherapy alone, significantly extended PFS in the liver by 7.9 months and resulted in a 31% reduction in risk of progression in the liver. PFS in the liver was a secondary endpoint in the SIRFLOX study.1

Median PFS in the liver

Subanalysis of patients stratified by hepatic tumor burden

The treatment effect following SIR-Spheres Y-90 resin microspheres was most evident in the patients with a greater baseline liver tumor burden (>12% of the liver having been replaced by tumor, a statistical cut-point that was pre-determined in order to identify potential predictors of Depth of Response).

In this group of more compromised patients, SIR-Spheres Y-90 resin microspheres was associated with a doubling of median PFS in the liver by competing risk analysis (27.2 vs.13.1 months; p=0.003).2

Patients who had a smaller liver tumor burden (≤12%) on study entry were more than six times as likely to experience a complete response or disappearance of all liver tumors following SIR-Spheres Y-90 resin microspheres compared to those who received only chemotherapy (11.3% vs.1.7%; p=0.003).2


bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
No statistically significant improvement of PFS at any site

1. van Hazel GA et al. J Clin Oncol 2016; 34: 1723–1731.
2. Heinemann V et al. ESMO WCGIC, Annals of Oncology 2016; 27 (Suppl 2): Abs. O-014.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.